INVESTABOT
Equity Research
XNYS · ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES
Includes notes from domestic 8-K and foreign private issuer 6-K disclosures.
Edwards Lifesciences (EW) had 1 Form 144 pre-sale notice filed on 2026-08-31. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed transaction.
Edwards Lifesciences (EW) had 1 Form 144 pre-sale notice filed on 2026-08-28. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed transaction.
TL;DR: Donald E. Bobo, Jr., Corporate Vice President of Strategy and Corporate Development at Edwards Lifesciences, has notified the company's board of his plan to retire by mid-year 2027.
Edwards Lifesciences (EW) had 2 Form 144 pre-sale notices filed on 2026-08-26. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed transaction.
Edwards Lifesciences (EW) had 1 Form 144 pre-sale notice filed on 2026-08-11. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed transaction. At least one…
Edwards Lifesciences (EW) had 1 Form 144 pre-sale notice filed on 2026-07-28. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed transaction.
Edwards Lifesciences (EW) had 2 Form 144 pre-sale notices filed on 2026-07-30. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed transaction.
Edwards Lifesciences (EW) had 1 Form 144 pre-sale notice filed on 2026-07-27. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed transaction.
Edwards Lifesciences (EW) had 1 Form 144 pre-sale notice filed on 2026-05-04. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed transaction.
Edwards Lifesciences (EW) had 1 Form 144 pre-sale notice filed on 2026-05-11. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed transaction.
Edwards Lifesciences (EW) had 2 Form 144 pre-sale notices filed on 2026-05-29. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed transaction.
Edwards Lifesciences (EW) had 1 Form 144 pre-sale notice filed on 2026-05-27. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed transaction.
Edwards Lifesciences (EW) had 1 Form 144 pre-sale notice filed on 2026-05-18. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed transaction. At least one…
Edwards Lifesciences (EW) had 1 Form 144 pre-sale notice filed on 2026-05-12. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed transaction. At least one…
Edwards Lifesciences (EW) had 1 Form 144 pre-sale notice filed on 2026-05-22. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed transaction.
Edwards Lifesciences (EW) had 1 Form 144 pre-sale notice filed on 2026-05-15. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed transaction.
TL;DR: Edwards Lifesciences reported Q1 2026 total sales of $1.65 billion, with its flagship TAVR segment growing 14.4% to $1.2 billion and EPS of $0.66 — strong enough that management raised full-year guidance…
open-market Form 4 only - grants, exercises, tax withholding excluded
0 buyers - 7 unique sellers · 6 accumulating - 6 trimming - 1 unchanged
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| September 14, 2026 | Markowitz Wayne | CVP, JAPAC | TAX_WITHHOLD | -568 | $84 | ~$48K |
| September 13, 2026 | Dahl Andrew M. | SVP, Corporate Controller | TAX_WITHHOLD | -253 | $84 | ~$21K |
| September 11, 2026 | Markowitz Wayne | CVP, JAPAC | TAX_WITHHOLD | -355 | $87 | ~$31K |
| September 11, 2026 | Lippis Daniel J. | CVP, TAVR | OPTION_EXERCISE | -619 | — | — |
| September 11, 2026 | Lippis Daniel J. | CVP, TAVR | SELL | -619 | $88 | ~$54K |
| September 11, 2026 | Lippis Daniel J. | CVP, TAVR | OPTION_EXERCISE | 619 | $73 | ~$45K |
| September 11, 2026 | Chopra Daveen | CVP, TMTT, Surgical & IHFM | TAX_WITHHOLD | -398 | $87 | ~$35K |
| August 31, 2026 | Dahl Andrew M. | SVP, Corporate Controller | SELL | -544 | $91 | ~$50K |
| August 28, 2026 | Bruls Annette | CVP, EMEACLA | SELL | -2,644 | $90 | ~$0.2M |
| August 26, 2026 | Chopra Daveen | CVP, TMTT, Surgical & IHFM | OPTION_EXERCISE | 31,800 | $73 | ~$2.3M |
| August 26, 2026 | Chopra Daveen | CVP, TMTT, Surgical & IHFM | SELL | -1,154 | $92 | ~$0.1M |
| August 26, 2026 | Chopra Daveen | CVP, TMTT, Surgical & IHFM | SELL | -30,646 | $91 | ~$2.8M |
| August 26, 2026 | Chopra Daveen | CVP, TMTT, Surgical & IHFM | OPTION_EXERCISE | -31,800 | — | — |
| August 26, 2026 | Markowitz Wayne | CVP, JAPAC | SELL | -1,240 | $91 | ~$0.1M |
| August 11, 2026 | Lippis Daniel J. | CVP, TAVR | OPTION_EXERCISE | 619 | $73 | ~$45K |
| August 11, 2026 | Lippis Daniel J. | CVP, TAVR | SELL | -619 | $92 | ~$57K |
| August 11, 2026 | Lippis Daniel J. | CVP, TAVR | OPTION_EXERCISE | -619 | — | — |
| July 30, 2026 | Markowitz Wayne | CVP, JAPAC | SELL | -146.31 | $86 | ~$13K |
| July 28, 2026 | Markowitz Wayne | CVP, JAPAC | OPTION_EXERCISE | 9,628 | $74 | ~$0.7M |
| July 28, 2026 | Markowitz Wayne | CVP, JAPAC | SELL | -9,628 | $85 | ~$0.8M |
| Date | Filer | Relationship | Est. shares | Filing |
|---|---|---|---|---|
| August 31, 2026 | Dahl Andrew M. | — | 544 | SEC |
| August 28, 2026 | Bruls Annette | — | 2,644 | SEC |
| August 26, 2026 | Markowitz Wayne | — | 1,240 | SEC |
| August 26, 2026 | Chopra Daveen | — | 31,800 | SEC |
| August 11, 2026 | Lippis Daniel J. | — | 1,857 | SEC |
| July 30, 2026 | Ullem Scott B. | — | 50,000 | SEC |
| July 30, 2026 | Markowitz Wayne | — | 147 | SEC |
| July 28, 2026 | Markowitz Wayne | — | 9,628 | SEC |
| July 27, 2026 | Zovighian Bernard J | — | 2,921 | SEC |
| May 29, 2026 | Ullem Scott B. | — | 64,152 | SEC |
| Date | Insider | Title | Relationship | Shares | Filing |
|---|---|---|---|---|---|
| June 1, 2026 | — | — | — | — | SEC |
| Institution | Shares | Value ($) | Change % | Filing date |
|---|---|---|---|---|
| Vanguard Group | 70,079,435 | ~$6.0B | — | January 29, 2026 |
| BlackRock | 58,789,433 | ~$5.3B | 11.5% | August 7, 2026 |
| BlackRock | 50,975,492 | ~$4.7B | — | August 13, 2024 |
| BlackRock | 52,461,915 | ~$4.5B | — | February 12, 2026 |
| BlackRock | 52,728,933 | ~$4.2B | 0.5% | May 13, 2026 |
| State Street | 26,321,940 | ~$2.4B | 0.1% | August 7, 2026 |
| JP Morgan Chase | 26,349,452 | ~$2.2B | — | February 11, 2026 |
| State Street | 25,991,524 | ~$2.2B | — | February 13, 2026 |
| State Street | 26,296,399 | ~$2.1B | 1.2% | May 15, 2026 |
| JP Morgan Chase | 23,053,175 | ~$2.1B | 5.3% | August 12, 2026 |
| JP Morgan Chase | 21,889,712 | ~$1.7B | -16.9% | May 13, 2026 |
| Fidelity (FMR) | 16,582,547 | ~$1.4B | — | February 17, 2026 |
| Fidelity (FMR) | 14,503,770 | ~$1.2B | -12.5% | May 15, 2026 |
| Fidelity (FMR) | 8,435,949 | ~$763.1M | -41.8% | August 13, 2026 |
| Morgan Stanley | 7,314,292 | ~$623.5M | — | May 27, 2026 |
| Morgan Stanley | 6,339,368 | ~$573.5M | -10.2% | August 13, 2026 |
| Morgan Stanley | 7,060,876 | ~$565.4M | -3.5% | May 15, 2026 |
| Millennium Management | 6,502,638 | ~$554.3M | — | February 17, 2026 |
| Goldman Sachs | 5,142,050 | ~$411.8M | 47.0% | May 15, 2026 |
| Goldman Sachs | 4,549,113 | ~$411.5M | -11.5% | August 14, 2026 |